In April 2009, the American Society of Clinical Oncology (ASCO) recommended that patients with metastatic CRC who are candidates for EGFR inhibitors have their tumor tested for KRAS mutations, and that those with a KRAS mutation in codon 12 or 13 not receive anti-EGFR treatment [3]. Here, EGFR is linked to neoplasm.